CritiTech Announces
Coating Agreement with Major Device Company
August 22, 2005
FOR IMMEDIATE RELEASE
Lawrence, Kan. - CritiTech announced today that
it signed an agreement with a major international device company
to develop improved processes for the coating of implantable
devices such as cardiac stents. CritiTech has numerous patents
using supercritical fluid technology for the production of
nano/micro particle pharmaceutical compounds and for the coating
of substrates.
“This demonstrates the progress that our
company has made in developing our coating technology. Through
an additional agreement with an international pharmaceutical
company, CritiTech intends to develop a variety of proprietary
methods for coating small particle compounds,” said
Crititech CEO and President Sam Campbell.
CritiTech provides critical drug delivery and
development technology for the pharmaceutical industry. CritiTech
produces fine-particle pharmaceuticals including nanoparticle
pharmaceuticals using patented technologies developed at the
University of Kansas. The processes use compressed carbon
dioxide as the processing medium to produce relatively residue-free
and uniform drug microparticles and coatings.
The pharmaceutical industry has exhibited substantial
interest in processes that produce improved formulations using
nanoparticulate drugs in order to extend the patent life of
an existing drug or to enable the delivery of a poorly soluble
compound. CritiTech has also successfully used its proprietary
technology to coat medicinal agents either on small particle
drugs for improved drug delivery or as a thin film on implantable
medical devices such as cardiac stents. The Nanotax™
ovarian cancer drug is the first drug to be announced under
the company’s drug development program.
|
